Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It contains specific transaction data related to share ownership:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Increase in notional interest via dividend re-investment under the 2009 Performance Share Plan.
- Transaction Date: July 14, 2016.
- Share Price: £16.285.
- Total Volume: 1,117.694 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an increase in shareholding for Mr. N Hirons (SVP, Global Ethics & Compliance) resulting from the automatic re-investment of dividends.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a mandatory regulatory disclosure of a specific equity transaction.
Investor Verification Points
- Verify the identity of the PDMR involved: Mr. N Hirons.
- Confirm the transaction was a non-cash dividend re-investment, not an open market purchase.
- Note that this filing does not reflect the company's broader financial performance for the period.